The UK is lagging behind other major markets in the world on research into the benefits of medicinal cannabis, according to a scientist specialising in the area.
Discussing her strong opinions on the state of cannabis science in the UK with CannIntelligence, Callie Seaman, scientist and co-founding director of AquaLabs, said that clinical trials in the UK were heavily biased towards harm reduction rather than focusing on the plant’s medicinal benefits.
Lorraine is responsible for writing news analysis and assisting with copy-editing. Lorraine is a copywriter and editor who has written and edited words for a wide range of audiences, from local community newspapers to consumer magazines and trade websites.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
LATEST ALERTS
